Resurgence of Covid-19 in Manaus, Brazil, despite high seroprevalence
thelancet.com
thelancet.com
Data is preliminary but based on previous metrics on exposure and “immunity” we shouldn’t see so many people getting sick. Also possible this is another “super contagious” strain and it is ripping its way across the remaining population that’s not immune. Also possible they just overestimated the number of people that should be immune (obviously this would be the ideal answer).
Everyone is sort of holding their breath that the vaccines will maintain immunity until “herd immunity” can be established. If the virus mutates so existing immunity no longer protects you then we’re sort of back to square one and this will be like fighting the flu where it never “goes away.”
It’s not really a question of if the virus will mutate to reinfect people again (or infect those vaccinated) but more of when and if we can get to herd immunity before that happens.
Please forgive me if this is a stupid question, this is not my knowledge domain.
>“Every time a new variant comes up we should be able to test whether or not [our vaccine] is effective,” Pfizer CEO Albert Bourla told Bloomberg news. “Once we discover something that is not as effective, we will very, very quickly be able to produce a booster dose that will be a small variation to the current vaccine.”
https://www.google.com/amp/s/www.timesofisrael.com/pfizer-mo...
> By the time the first American death was announced a month later, the vaccine had already been manufactured and shipped to the National Institutes of Health for the beginning of its Phase I clinical trial.
https://nymag.com/intelligencer/2020/12/moderna-covid-19-vac...
Secondly, Manaus is apparently a hospital the serves a pretty vast rural area, so the hospitalizations may be catching a lot of people that would have fallen outside of the immediate area covered by the seroprevalence survey.
> There are at least four non-mutually exclusive possible explanations for the resurgence of COVID-19 in Manaus.
1. wrong case reproduction number (R0) of 3
2. waning immunity
3. a new immunity evading variant
4. a more transmissible variant with a higher effective reproductive number
I'd say the simplest explanation is that the 76% seroprevalence study was wrong.